The chapter analyzes the efficacy and risks of PCSK9 inhibitors like evolocumab and alirocumab, comparing them to statins in terms of cardiovascular benefits and adverse effects. It delves into the mechanism of action of these drugs, their impact on mortality rates, and the challenges in evaluating their risk versus reward due to limited usage and high cost. The conversation also explores the complexities of assessing cardiovascular risk factors beyond just LDL cholesterol levels, emphasizing a comprehensive approach to improve heart health.
Today, Paul and Mike unpack their opinions about lipids. They talk about true risk for cardiovascular disease, primary versus secondary prevention, lipid lowering drugs, and share their thoughts on a recent podcast episode with Peter Attia.
*Produced by Mountain Valley Media
00:06:08 Blood markers & imaging techniques of metabolic function
00:14:38 Gene mutations
00:20:28 LDL & Plaque burden
00:27:23 Money in statins
00:31:38 Downsides of lowering LDL
01:21:23 The downsides of popular cholesterol lowering drugs
01:41:07 Should we fear heart attacks?
01:45:23 PCSK9 Inhibitors
01:52:43 Risk profile of Statins
01:53:02 Risk vs. reward of Ezetimibe
02:04:02 Primary vs. secondary prevention
Resources:
Debunking Sugar Claims: What Dr. Lustig Got Wrong On The Huberman Podcast:
https://www.youtube.com/watch?v=JcEmSgbMfco&t=2933s
Work With Mike: https://mikefave.com/